Adalimumab is a human monoclonalIgG1antibody targeting tumour necrosis factor α (TNF-α).

TNF-α^[1]

Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study^[2].

The elimination half-life (t_1/2) of Adalimumab is long (~20 days)^[1]. The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr^-/-mice^[2].

145425.42

Liquid

331731-18-1

阿达木单抗；阿达莫单抗

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.